October 11, 2023

Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023

Press Release

 

PARSIPPANY, N.J.–Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, the presentation of nine scientific presentations with data from its current anti-infective portfolio at Infectious Disease Week (IDWeek) 2023, taking place October 11-15, 2023, in Boston, MA.  

IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).

Details of the presentations are provided below. The complete program of titles and abstracts can be accessed on the IDWeek 2023 website at www.idweek.org.

Melinta Portfolio Poster and Oral Presentations

Product and Presentation Type

Date/Time/ Location

Title

Poster number

 

Oritavancin

(poster)

Thursday,  October 12

12:15 PM – 1:30 PM

 

Trend Analysis of Oritavancin and Comparator Agents Activity against Enterococcus Causing Infections in US Medical Centers between 2017–2019 and 2022

 

734

 

Oritavancin

(poster)

Friday,       October 13

12:15 PM – 1:30 PM

Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Skin Structure Infections in US Medical Centers between 2017–2019 and 2022

 

1812

 

Rezafungin

(poster)

Saturday, October 14

12:15 PM – 1:30 PM

 

Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program

 

 

2115

 

Rezafungin

(oral)

Friday, October 13

1:45-3:00 PM

Room 102AB

Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)

 

 

 

Oral presentation

 

 

Meropenem and Vaborbactam

(poster)

Saturday, October 14

12:15 PM – 1:30 PM

Activity of meropenem-vaborbactam tested against Burkholderia species isolates

2757

 Meropenem and Vaborbactam

(poster)

Saturday, October 14

12:15 PM – 1:30 PM

 

 

 

Comparative Effectiveness of Meropenem/Vaborbactam vs. Ceftazidime/Avibactam among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021

2816

Meropenem and Vaborbactam

(poster)

Saturday, October 14

12:15 PM – 1:30 PM

 

 

 

Outcomes of Timely vs. Delayed Meropenem/Vaborbactam Treatment of Infections with CRE among Adults Hospitalized in the US, 2019-2021

2817

Meropenem and Vaborbactam

(poster)

Friday October 13

 

 

PK, Safety and Tolerability of VABOMERE® (meropenem-vaborbactam) in Infants, Children and Adolescents

1676

Delafloxacin

(poster)

Saturday, October 14

 

 

 

Delafloxacin and Comparator Fluoroquinolone In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022)

2754

 

About Melinta Therapeutics 

Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients.Our portfolio currently includes seven commercial-stage products: BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), REZZAYO™ (rezafungin for injection), TOPROL-XL® (metoprolol succinate) and VABOMERE® (meropenem and vaborbactam). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit Melinta.com.  
 

Melinta Media Relations Contact: 
Sharon Dilling 
Sr. Director, Corporate Communications 
Melinta Therapeutics 
sdilling@melinta.com